Ray Tancredi of Walgreens Give an Outlook on Oncology Drugs, Other Standouts in the Pipeline
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been many oncology drug approvals. Over time, the number of approvals decreased each year.
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been good number of oncology drug approvals. Over time, number of approvals each year have dropped down from 22, to 19 and so on.
As of 2023, there's only been two drugs approved, Tancredi sees that "there could be three or four drugs approved before the end of this year, maybe more." There's a number of products in the pipeline that could get approved this year.
"So when it's all said and done at the end of 2023, you know, we could be in double digits again, for as far as approvals are concerned," he added.
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
